Srini Srinivas
Senior Medical Director Novartis
Seminars
This workshop is designed for business development professionals, biotech leaders, market access teams, and clinical development strategists working to strengthen the commercial foundations of rare kidney disease therapies. While scientific innovation in nephrology is accelerating, many programs struggle to translate clinical success into sustainable reimbursement and investment due to misalignment between development strategies, payer expectations, and pricing models.
This session will explore how clinical evidence, value demonstration, and pricing strategy can be aligned earlier in development to support stronger market access and investment readiness, helping teams integrate commercial thinking across the development lifecycle.
Dive into:
- Understanding payer and HTA expectations and how these should inform evidence generation, endpoint selection, and clinical trial design
- Developing pricing and value frameworks for rare kidney disease therapies, including how to articulate clinical and economic value to payers
- Building the strategic skills to evaluate commercial viability early, helping teams align clinical development decisions with reimbursement and investment considerations
- Explore how advances in disease biology and molecular characterization are enabling more precise patient segmentation across rare and genetic kidney diseases
- Discuss how diagnostic strategies, biomarker approaches, and assay validation considerations can support the identification of patients most likely to respond to targeted therapies
- Examine how scientific, industry, and regulatory perspectives can align to inform precision-based trial design, therapeutic development strategies, and future approval pathways
